References
1. Chen Q, Ayer T, Bethea E, et al. Changes in hepatitis C burden and treatment trends in Europe during the era of direct-acting antivirals: a modelling study. BMJ Open. 2019;9:e026726.
2. Cooke GS, Andrieux-Meyer I, Applegate TL, et al. Accelerating the elimination of viral hepatitis: A Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol. 2019;4:135-84. Fe de erratas: Lancet Gastroenterol Hepatol. 2019;4(5):e4.
3. Grupo de trabajo del estudio de prevalencia de la infección por hepatitis C en población general en España; 2017-2018. Resultados del 2º Estudio de Seroprevalencia en España (2017-2018). Ministerio de Sanidad, Consumo y Bienestar Social; 2019.
4. Aguinaga A, Diaz-Gonzalez J, Perez-Garcia A, et al. The prevalence of diagnosed and undiagnosed hepatitis C virus infection in Navarra, Spain, 2014-2016. Enferm Infecc Microbiol Clin. 2018;36:325-31.
5. Rodríguez-Tajes S, Dacal Y, Collazos C, et al. Estudio de prevalencia de infección por los virus hepatitis B y C en Cataluña. 42 congreso anual de la Asociación Española para el Estudio del Hígado. Madrid, 16 de febrero de 2017.
6. Fernández-Bermejo M, Íñiguez R, Mata P, et al. Estudio de prevalencia de serología de hepatitis C en un área de salud con población rural. 42 congreso anual de la Asociación Española para el Estudio del Hígado. Madrid, 15-17 de febrero de 2017.
7. Cuadrado A, Perello C, Llerena S, et al. Design and cost effectiveness of a hepatitis C virus elimination strategy based on an updated epidemiological study (ETHON cohort). J Hepatol 2018; Supplement 1, S164.
8. Secretaría General de Sanidad y Consumo. Ministerio de Sanidad, Consumo y Bienestar Social. Plan Estratégico para el Abordaje de la Hepatitis C en el Sistema Nacional de Salud (PEAHC). Octubre 2018. [Citado: 19 de octubre de 2019]. Disponible en: https://www.mscbs.gob.es/ciudadanos/enfLesiones/enfTransmisibles/hepatitisC/PlanEstrategicoHEPATITISC/home.htm
9. Greenaway C, Makarenko I, Chakra CNA, et al. The Effectiveness and Cost-Effectiveness of Hepatitis C Screening for Migrants in the EU/EEA: A Systematic Review. Int J Environ Res Public Health. 2018;15(9).
10. World Health Organization Regional Office for Europe. Action Plan for the Health Sector Response to Viral Hepatitis in the WHO European Region; WHO/Europe: Copenhagen, Denmark, 2016.
11. World Health Organization. Combating hepatitis B and C to reach elimination by 2030. Advocacy brief. WHO: Geneva, Switzerland, May, 2016.
12. UK National Screening Committee. The definition of screening. [Citado: 9 de octubre de 2019]. Disponible en: https://webarchive.nationalarchives.gov.uk/20150408180051/http://www.screening.nhs.uk/screening.
13. Ministerio de Sanidad y Política Social. Documento marco sobre cribado poblacional. Diciembre de 2010. [Citado: 7 de octubre de 2019]. Disponible en: https://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/documentomarcoCribado.htm
14. Strong K, Wald N, Miller A, et al. Current concepts in screening for noncommunicable disease: World Health Organization Consultation Group Report on methodology of noncommunicable disease screening. J Med Screen. 2005;12:12-9.
15. Servicio Cántabro de Salud. Estrategia para la eliminación de la hepatitis C en Cantabria. Consultado el 31 de octubre de 2019. Disponible en: http://www.scsalud.es/documents/ 2162705/2529917/Hepatitis+C.pdf
16. Servicio Canario de Salud. Plan de Prevención de la Infección por Hepatitis en Canarias. Consultado el 31 de octubre de 2019. Disponible en: https://www3.gobiernodecanarias.org/sanidad/scs/contenidoGenerico.jsp?idDocument=25f382f5-46d9-11e3-a0f5-65699e4ff786&idCarpeta=5993c79b-a98e-11dd-b574-dd4e320f085c
17. Consejería de Sanidad. Dirección General de Coordinación de Atención al Ciudadano y Humanización de la Asistencia Sanitaria. Libro Blanco de la Hepatitis C en la Comunidad de Madrid 2016-2019. Edición: Julio 2017. Consultado el 31 de octubre de 2019. Disponible en: http://www.comunidad.madrid/publicacion/1354663261085
18. Crespo J, Albillos A, Buti M, et al. Eliminación de la hepatitis C. Documento de posicionamiento de la Asociación Española para el Estudio del Hígado (AEEH). Gastroenterol Hepatol. 2019;42:579-92.
19. Younossi Z, Park H, Henry L, et al. Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden. Gastroenterology. 2016;150:1599-608.
20. Oliva-Moreno J, Pena-Longobardo LM, Alonso S, et al. Labour productivity losses caused by premature death associated with hepatitis C in Spain. Eur J Gastroenterol Hepatol. 2015;27:631-7.
21. Calleja JL, Lens S, Fernández-Bermejo M, et al. Definition of the profiles of hepatitis C virus patients based on the identification of risky practices in Spain. Rev Esp Enferm Dig 2019; 111:731-37.
22. WHO guidelines on hepatitis B and C testing. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO.
23. Alarcón-Linares ME, Torres-Cantero A, Subirá C, et al. Geographic analysis and estimation of hepatitis C cases in migrant populations living in Spain: is a country-based screening strategy appropriate?. Rev Esp Enferm Dig 2019; 111:615-25.
24. Brochado-Kith Ó, Gómez Sanz A, Real LM, et al. MicroRNA Profile of HCV Spontaneous Clarified Individuals, Denotes Previous HCV Infection. J Clin Med. 2019;8(6). pii: E849. doi: 10.3390/jcm8060849.
25. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236.
26. Papatheodoridis GV, Hatzakis A, Cholongitas E, et al. Hepatitis C: The beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe. J Viral Hepat. 2018;25 Suppl 1:6-17.
27. Gomez-Escolar L, García A, Sáez I, et al. Screening of hepatitis C virus infection in adult general population in Spain. Eur J Gastroenterol Hepatol. 2018;30:1077-81.
28. Buti M, Dominguez-Hernandez R, Casado MA, et al. Healthcare value of implementing hepatitis C screening in the adult general population in Spain. PLoS One. 2018;13(11):e0208036.
29. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018;69:461-511.
30. Crespo J, Eiros JM, Blasco AJ, et al. The efficiency of several one-step testing strategies for the diagnosis of hepatitis C. Rev Esp Enferm Dig. 2019;111:10-6. doi: 10.17235/reed.2018.5810/2018.
31. Chevaliez S, Poiteau L, Rosa I, et al. Prospective assessment of rapid diagnostic tests for the detection of antibodies to hepatitis C virus, a tool for improving access to care Clin Microbiol Infect 2016; 22: 459.e1-459.e6.
32. Shivkumar S, Peeling R, Jafari Y, et al. Accuracy of Rapid and Point-of-Care Screening Tests for Hepatitis C: A Systematic Review and Meta-analysis. Ann Intern Med. 2012;157:558-66.
33. García F, Domínguez-Hernández R, Casado M, et al. The simplification of the diagnosis process of chronic hepatitis C is cost-effective strategy. Enferm Infecc Microbiol Clin. 2019; pii: S0213-005X(19)30143-0. doi: 10.1016/j.eimc.2019.03.001. [Epub ahead of print]
34. Canadian Task Force on Preventive Health Care. Recommendations on hepatitis C screening for adults. CMAJ. 2017;189:E594-604.
35. Screening for hepatitis C virus: a systematic review. Ottawa: CADTH; 2017 Mar. (CADTH health technology assessment; no.144).
36. Moyer VA; U.S. Preventive Services Task Force. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013;159:349-57.
37. World Health Organization. Guidelines for the Screening Care and Treatment of Persons with Chronic Hepatitis C Infection: Updated Version. 2016.
38. Hepatitis C Virus Infection Consensus Statement Working Group. Australian recommendations for the management of hepatitis C virus infection: a consensus statement (September 2018). Melbourne: Gastroenterological Society of Australia, 2018.
39. Buti M, Crespo J, García F. Diagnóstico de la hepatitis C en un solo paso. Consultado el 13 de noviembre de 2019. Disponible en: https://seimc.org/ficheros/gruposdeestudio/gehep/dcientificos/documentos/gehep-dc-2018-Diagnostico_en_un_paso_HepatitisC.pdf/3707-2618
40. Crespo J, Lázaro de Mercado P, Blasco Bravo AJ, et al. Diagnosis of hepatitis C virus infection in Spain: An opportunity to improve. Enferm Infecc Microbiol Clin. 2019;37:231-8.
41. AASLD-IDSA HCV Guidance Panel. Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clin Infect Dis. 2018;67:1477-92.
42. Marks K, Naggie S. Management of Hepatitis C in 2019. JAMA. 2019 May 17. doi: 10.1001/jama.2019.5353. [Epub ahead of print].
43. Cooke GS, Andrieux-Meyer I, Applegate TL, et al. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol. 2019;4:135-84.
44. Buti M, Calleja JL, Garcia-Samaniego J, et al. Elimination of hepatitis C in Spain: Adaptation of a mathematical model based on the public health strategic plan for addressing hepatitis C in the National Health System. Med Clin (Barc ). 2017;148:277-82.
45. Goñi S, Juanbeltz R, Martínez-Baz I, et al. Long-term changes on health-related quality of life in patients with chronic hepatitis C after viral clearance with direct-acting antiviral agents. Rev Esp Enferm Dig. 2019;111:445-52.
46. Ministerio de Sanidad, Servicios Sociales e Igualdad. Plan estratégico para el abordaje de la hepatitis C en el sistema nacional de salud. Actualización línea estratégica 2. Madrid; 2017. Consultado el 27 de septiembre de 2019. Disponible en: https://www.mscbs.gob.es/ciudadanos/enfLesiones/enfTransmisibles/hepatitisC/PlanEstrategicoHEPATITISC/docs/actualizacionEstrategiaTerapeuticaJunio2017.pdf
47. Mar J, Ibarrondo O, Martinez-Baz I, et al. Economic evaluation of a population strategy for the treatment of chronic hepatitis C with direct-acting antivirals. Rev Esp Enferm Dig. 2018;110:621-8.
48. Turnes J, Dominguez-Hernandez R, Casado MA. Value and innovation of direct-acting antivirals: long-term health outcomes of the strategic plan for the management of hepatitis C in Spain. Rev Esp Enferm Dig. 2017;109:809-17.
49. Guías AEEH/SEIMC de manejo de la Hepatitis C. 2107. Consultado el 1 de octubre de 2019. Disponible en: http://aeeh.es/wp-content/uploads/2017/06/consenso.pdf
50. Albillos A, Cañada JL, Molero JM, Pérez S, Pérez F, Simón MA, Turnes J; AEEH, SEMERGEN, semFYC, SEMG. Consenso de recomendaciones para el diagnóstico precoz, la prevención y la atención clínica de la hepatitis C en Atención Primaria. Madrid: Luzán 5; 2017.
51. Terrault NA, Hassanein T. Management of the patient with SVR. J Hepatol. 2016;65(1 Suppl):S120-S129.
52. Carrat F, Fontaine H, Dorival C, et al. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet. 2019;393:1453-64.
53. Alavi M, Law MG, Valerio H, et al. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia. J Hepatol. 2019;71:281-8.
54. Pascasio JM, Vinaixa C, Ferrer MT, et al. Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation. J Hepatol. 2017;67:1168-76.
55. Crespo G, Trota N, Londoño MC, et al. The efficacy of direct anti-HCV drugs improves early post-liver transplant survival and induces significant changes in waiting list composition. J Hepatol. 2018;69:11-7.
56. Kanwal F, Kramer J, Asch SM, et al. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. Gastroenterology. 2017;153:996-1005.
57. Kanwal F, Kramer JR, Asch SM, et al. Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents. Hepatology. 2019 Jun 20. doi: 10.1002/hep.30823. [Epub ahead of print].
58. Cacoub P, Desbois AC, Comarmond C, et al. Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis. Gut. 2018;67:2025-34.
59. Butt AA, Yan P, Shuaib A, et al. Direct-Acting Antiviral Therapy for HCV Infection Is Associated With a Reduced Risk of Cardiovascular Disease Events. Gastroenterology. 2019;156:987-96.
60. Sacristán JA, Oliva J, Campillo-Artero C, et al. ¿Qué es una intervención sanitaria eficiente en España en 2020? Gac Sanit. 2019. https://doi.org/10.1016/j.gaceta.2019.06.007 [Epub ahead of print].
61. Lazarus JV, Picchio C, Dillon JF, et al. Too many people with viral hepatitis are diagnosed late-with dire consequences. Nat Rev Gastroenterol Hepatol. 2019;16:451-2.
62. Crespo J, Cuadrado A, Perelló C, et al. Epidemiology of hepatitis C virus infection in a country with universal access to direct-acting antiviral agents: data for designing a cost-effective elimination policy in Spain. J Viral Hepat. 2019 Nov 22. doi: 10.1111/jvh.13238. [Epub ahead of print].